Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

References for PMC Articles for PubMed (Select 20624956)

1.

Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.

Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A.

Cancer Res. 2009 Dec 15;69(24):9385-94. doi: 10.1158/0008-5472.CAN-09-0494. Epub .

2.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

3.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.

Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.

4.

Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.

Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON.

Int Immunol. 2009 Feb;21(2):155-65. doi: 10.1093/intimm/dxn133. Epub 2008 Dec 23.

5.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.

J Clin Oncol. 2008 Nov 10;26(32):5233-9. doi: 10.1200/JCO.2008.16.5449. Epub 2008 Sep 22.

6.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A.

J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.

7.

Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.

Nat Rev Cancer. 2008 Apr;8(4):299-308. doi: 10.1038/nrc2355. Review.

8.

Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.

Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM.

Cancer Immunol Immunother. 2008 Sep;57(9):1279-89. doi: 10.1007/s00262-008-0461-1. Epub 2008 Feb 6.

9.

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.

Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP.

J Clin Invest. 2007 Feb;117(2):492-501.

10.

Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, Greenberg PD.

Blood. 2007 Mar 15;109(6):2331-8. Epub 2006 Nov 2.

11.

Cancer regression in patients after transfer of genetically engineered lymphocytes.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.

Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.

12.

CD8+ T-cell memory in tumor immunology and immunotherapy.

Klebanoff CA, Gattinoni L, Restifo NP.

Immunol Rev. 2006 Jun;211:214-24. Review.

13.

Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography.

Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, Gambhir SS.

Cancer Gene Ther. 2005 Mar;12(3):329-39.

PMID:
15592447
14.

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA.

Nat Biotechnol. 2004 May;22(5):589-94. Epub 2004 Apr 4. Erratum in: Nat Biotechnol. 2004 Dec;22(12):1590. Nat Biotechnol. 2004 Jun;22(6):760.

PMID:
15064769
15.

CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.

Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI.

J Immunol. 2003 Mar 1;170(5):2582-9.

16.

Quantitative imaging of the T cell antitumor response by positron-emission tomography.

Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, Gambhir SS, Witte ON.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1232-7. Epub 2003 Jan 23.

17.

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. Epub 2002 Nov 11.

19.

T-cell-receptor gene therapy.

Schumacher TN.

Nat Rev Immunol. 2002 Jul;2(7):512-9. Review.

PMID:
12094225
20.

MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.

Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ, Rosenberg SA.

Cancer Res. 1999 Dec 15;59(24):6230-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk